News | Cardiovascular Ultrasound | July 14, 2021

Speckle Tracking Strain Echo May Predict Heart Complications From COVID-19

Cardiac ultrasound strain may be able to detect atrial fibrillation onset in COVID patients to enable earlier intervention and predict outcomes

An example of a strain echo from the study showing reduced peak longitudinal/reservoir left atrial strain in a COVID-19 patient who developed atrial fibrillation during admission. Average left atrial strain here is 20% (normal should be above 38%).

An example of a strain echo from the study showing reduced peak longitudinal/reservoir left atrial strain in a COVID-19 patient who developed atrial fibrillation during admission. Average left atrial strain here is 20% (normal should be above 38%). Read the study.


July 13, 2021 — Researchers at Johns Hopkins Medicine have shown that speckle-tracking strain echocardiograms may predict which patients with COVID-19 are most at risk of developing atrial fibrillation (AF). The findings, published online May 30 in the Journal of the American Society of Echocardiography (JASE), also suggest patients with COVID-19 who go on to develop atrial fibrillation more commonly have elevated levels of  troponin and NT-proBNP. 

If further studies confirm the findings, “this could lead to new therapies to prevent strokes and heart attacks in certain COVID-19 patients who are at the highest risk,” said Allison Hays, M.D., medical director of echocardiography programs at The Johns Hopkins Hospital and senior author of the published paper.

The COVID-19 pandemic has affected more than 170 million people around the world, and previous studies of complications and long-term effects of SARS-CoV-2 infection have found that patients who are hospitalized with COVID-19 have more than double the rate of arrhythmias, including atrial fibrillation and atrial flutter, a similar rapid rhythm that can lead to heart failure and stroke. But exactly how the virus causes these heart complications, and who is most at risk of developing AFib because of COVID-19, has been poorly understood.

In this study, Hays and her colleagues compared 80 patients with COVID-19 with 34 patients who did not have COVID-19 who were also treated at The Johns Hopkins Hospital in the intensive or intermediate care units for respiratory issues. None of the patients had a history of heart arrhythmia.

In the study, carried out between March and June 2020, the researchers analyzed cardiac ultrasounds of hospitalized patients, applying a special kind of analysis called speckle-tracking strain to determine how well the left atrium of the heart moves with each heartbeat.

The team found that, overall, patients with COVID-19 had reduced function of their left atrium, the chamber of the heart that receives oxygenated blood from the lungs. Left atrial strain (a measure of the movement of the left atrium’s walls) was significantly lower in patients with COVID-19 (28.2% compared with 32.6%, p=0.026; normal >38%) and left atrial emptying fraction was also lower in the patients with COVID-19 (55.7% compared with 64.1%, p<0.001).

Moreover, left atrial strain was even lower among the 30% of patients with COVID-19 who developed atrial fibrillation or flutter during their hospital stay compared with other patients with COVID-19 (22.3% compared to 30.4%, p<0.001). This suggests that speckle-tracking analysis — and specifically, left atrial strain measurement — could be used to predict which patients with COVID-19 are at highest risk of arrhythmias and develop preventive treatments.

“A lot of patients already get echocardiograms while in the hospital; the addition of strain analysis requires no extra scanning of the patient,” said Erin Goerlich, M.D., a cardiology fellow at the Johns Hopkins University School of Medicine and first author of the new paper. “So this is a safe and affordable new data point that can clue us in about who might develop atrial fibrillation.” Echocardiograms cost on average about $2,000, and are generally covered by health insurance.

When the researchers looked at the blood samples of patients with COVID-19 who developed atrial fibrillation, they saw some differences compared with other patients with the virus. People who developed AF had higher levels of troponin (0.07 versus 0.03, p=0.011) and NT-proBNP (946 versus 231, p=0.0007), two known markers of heart stress.

“This tells us that COVID-19 patients with high levels of these biomarkers should be followed more closely and may benefit from an echocardiogram,” Goerlich explained.

Hays cautioned that the current study didn’t test whether treating patients with COVID-19 with blood thinners could help prevent the complications that can result from atrial fibrillation, which has been suggested by some clinicians. Blood thinners are generally prescribed to atrial fibrillation patients to lower the risk of blood clots and strokes.

However, the new study suggests that treating certain people — those with especially low left atrial strain, for instance — could be one path forward. More research is needed in this area, Hays says.

“We’re also actively studying how these effects on the heart might persist after SARS-CoV-2 infection,” she adds. “It’s important to know whether those measures of strain and emptying fraction improve over time.”

In addition to Allison Hays and Erin Goerlich, other authors on the JASE paper are Anum Minhas, Nisha Gilotra, Andreas Barth, Monica Mukherjee, Allyso Parziale and Katherine Wu of the Johns Hopkins University School of Medicine.

The research was supported by a Ruth L. Kirschstein Institutional National Research Service Award (T32HL007227); the National Heart, Lung, and Blood Institute (T32HL007024 and 1R01HL147660); the Magic That Matters Fund of Johns Hopkins Medicine; and a Johns Hopkins Clinician Scientist Award.

Related Cardiac Ultrasound and COVID Content:

Echocardiography Related COVID-19 Research Presented at ASE 2021

VIDEO: Artificial Intelligence Identifies High-Risk COVID Patients From Cardiac Ultrasounds — Interview with Federico Asch, M.D.

Handheld Ultrasound Helps to Monitor COVID-19 Patients With Cardiac Conditions

Overview of Trials for Anticoagulation Therapy for COVID-19 Patients

 

VIDEO: An Overview of Echo Strain Imaging — Interview with Marielle Scherrer-Crosbie, M.D.

Global Longitudinal Strain Echo Offers Early Detection of Cardiotoxicity Heart Damage From Chemotherapy

Find more cardiology related COVID-19 content

Reference:

1. Erin Goerlich, Anum Minhas, Nisha Gilotra, Allyson Parziale, Katherine C. Wu, Allison G. Hays, et al. Left atrial function in patients with COVID-19 and its association with incident atrial fibrillation/flutter. American Society of Echocardiography. Published online May 30, 2021. DOI:https://doi.org/10.1016/j.echo.2021.05.015.
 


Related Content

News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
Subscribe Now